Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with AML.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
  • Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
  • Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
  • Address patient-specific challenges surrounding pre- and posttransplant processes and novel agents to mitigate risk
  • Manage treatment-related toxicities associated with novel therapeutics
Additional information
Supporters: 

Supported by an independent educational grant from AbbVie
Supported by an independent medical education grant from Bristol Myers Squibb
Supported by an educational grant from Genentech, a member of the Roche Group

Course summary
Available credit: 
  • 2.50 AAPA Category 1 CME credit
  • 2.50 ACPE contact hours
  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 ANCC contact hours
  • 2.50 Participation
Course opens: 
12/10/2021
Course expires: 
02/06/2022
Cost:
$0.00

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel A. Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 2.5 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 2.5 contact hours (0.25 CEUs) of continuing education credit. UAN: JA4008196-0000-21-099-L01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 2.50 AAPA Category 1 CME credit
  • 2.50 ACPE contact hours
  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 ANCC contact hours
  • 2.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button above to access the evaluation.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing